Literature DB >> 19295143

Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.

Chee Yeun Chung1, James B Koprich, Hasan Siddiqi, Ole Isacson.   

Abstract

Little is known about key pathological events preceding overt neuronal degeneration in Parkinson's disease (PD) and alpha-synucleinopathy. Recombinant adeno-associated virus 2-mediated delivery of mutant (A53T) human alpha-synuclein into the substantia nigra (SN) under a neuron-specific synapsin promoter resulted in protracted neurodegeneration with significant dopaminergic (DA) neuron loss by 17 weeks. As early as 4 weeks, there was an increase in a dopamine metabolite, DOPAC and histologically, DA axons in the striatum were dystrophic with degenerative bulbs. Before neuronal loss, significant changes were identified in levels of proteins relevant to synaptic transmission and axonal transport in the striatum and the SN. For example, striatal levels of rabphilin 3A and syntaxin were reduced. Levels of anterograde transport motor proteins (KIF1A, KIF1B, KIF2A, and KIF3A) were decreased in the striatum, whereas retrograde motor proteins (dynein, dynamitin, and dynactin1) were increased. In contrast to reduced levels in the striatum, KIF1A and KIF2A levels were elevated in the SN. There were dramatic changes in cytoskeletal protein levels, with actin levels increased and alpha-/gamma-tubulin levels reduced. In addition to these alterations, a neuroinflammatory response was observed at 8 weeks in the striatum, but not in the SN, demonstrated by increased levels of Iba-1, activated microglia and increased levels of proinflammatory cytokines, including IL-1beta, IFN-gamma and TNF-alpha. These results demonstrate that changes in proteins relevant to synaptic transmission and axonal transport coupled with neuroinflammation, precede alpha-synuclein-mediated neuronal death. These findings can provide ideas for antecedent biomarkers and presymptomatic interventions in PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295143      PMCID: PMC2693917          DOI: 10.1523/JNEUROSCI.5427-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  32 in total

1.  Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport.

Authors:  Györgyi Szebenyi; Gerardo A Morfini; Alyssa Babcock; Milena Gould; Kimberly Selkoe; David L Stenoien; Maureen Young; Pieter W Faber; Marcy E MacDonald; Michael J McPhaul; Scott T Brady
Journal:  Neuron       Date:  2003-09-25       Impact factor: 17.173

2.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.

Authors:  J E Galvin; K Uryu; V M Lee; J Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

3.  Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys.

Authors:  P Apicella; E Trouche; A Nieoullon; E Legallet; N Dusticier
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

4.  Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.

Authors:  H Li; S H Li; Z X Yu; P Shelbourne; X J Li
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

5.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man.

Authors:  Lindsey R Fischer; Deborah G Culver; Philip Tennant; Albert A Davis; Minsheng Wang; Amilcar Castellano-Sanchez; Jaffar Khan; Meraida A Polak; Jonathan D Glass
Journal:  Exp Neurol       Date:  2004-02       Impact factor: 5.330

6.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

7.  Fetal homotypic transplant in the excitotoxically neuron-depleted thalamus: light microscopy.

Authors:  M Peschanski; O Isacson
Journal:  J Comp Neurol       Date:  1988-08-15       Impact factor: 3.215

8.  Altered proteasomal function in sporadic Parkinson's disease.

Authors:  Kevin St P McNaught; Roger Belizaire; Ole Isacson; Peter Jenner; C Warren Olanow
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

9.  Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease.

Authors:  Rosario Sánchez-Pernaute; Andrew Ferree; Oliver Cooper; Meixiang Yu; Anna-Liisa Brownell; Ole Isacson
Journal:  J Neuroinflammation       Date:  2004-05-17       Impact factor: 8.322

10.  Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.

Authors:  María Clara Pott Godoy; Rodolfo Tarelli; Carina Cintia Ferrari; Maria Inés Sarchi; Fernando Juan Pitossi
Journal:  Brain       Date:  2008-05-26       Impact factor: 13.501

View more
  168 in total

1.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

Authors:  Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K Tofaris; Michel Goedert; Maria Grazia Spillantini
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

2.  Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.

Authors:  Yaping Chu; Gerardo A Morfini; Lori B Langhamer; Yinzhen He; Scott T Brady; Jeffrey H Kordower
Journal:  Brain       Date:  2012-06-19       Impact factor: 13.501

Review 3.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

4.  Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson's disease.

Authors:  Marta Carmo; Francisco Q Gonçalves; Paula M Canas; Jean-Pierre Oses; Francisco D Fernandes; Filipe V Duarte; Carlos M Palmeira; Angelo R Tomé; Paula Agostinho; Geanne M Andrade; Rodrigo A Cunha
Journal:  Br J Pharmacol       Date:  2019-08-01       Impact factor: 8.739

5.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Authors:  Martin Lundblad; Mickael Decressac; Bengt Mattsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

6.  Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.

Authors:  Tian-Fang Jiang; Ying-Jie Zhang; Hai-Yan Zhou; Hong-Mei Wang; Li-Peng Tian; Jun Liu; Jian-Qing Ding; Sheng-Di Chen
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-17       Impact factor: 4.147

Review 7.  Microtubule Destabilization Paves the Way to Parkinson's Disease.

Authors:  D Cartelli; G Cappelletti
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

8.  Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.

Authors:  Chee Yeun Chung; James B Koprich; Penelope J Hallett; Ole Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

9.  Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Authors:  Poonam Thakur; Ludivine S Breger; Martin Lundblad; Oi Wan Wan; Bengt Mattsson; Kelvin C Luk; Virginia M Y Lee; John Q Trojanowski; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

10.  Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin.

Authors:  Jing Jin; Yong Cheng; Yongqing Zhang; William Wood; Qi Peng; Emmette Hutchison; Mark P Mattson; Kevin G Becker; Wenzhen Duan
Journal:  J Neurochem       Date:  2012-09-28       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.